Results 281 to 290 of about 29,210 (297)

Fluconazole Increases Ibrutinib Concentration

American Journal of Therapeutics, 2020
Toyotaka Kawamata, Takeo Yasu, Seiichirou Kuroda, Kenji Momo   +3 more
openaire   +3 more sources

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

Nature Medicine, 2018
Rishu Agarwal, Yih-Chih Chan, Constantine S Tam   +2 more
exaly  

Ibrutinib: searching for a partner drug

The Lancet Oncology, 2019
Arnon P. Kater, Jennifer R. Brown
openaire   +3 more sources

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma

Cancer Discovery, 2017
Christian Grommes, Alessandro Pastore, Nicolaos J Palaskas   +2 more
exaly  

Ventricular Tachycardia Caused by Ibrutinib

The Journal of Emergency Medicine, 2017
János Tomcsányi, Zoltán Mátrai, Kristóf Tomcsányi   +2 more
openaire   +3 more sources

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Cancer Discovery, 2018
Bonnie K Harrington, Kerry A Rogers, Farrukh T Awan   +2 more
exaly  

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Lancet Oncology, The, 2016
Fatih Demirkan, Jiri Mayer, Nancy L Bartlett   +2 more
exaly  

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Journal of Clinical Oncology, 2019
Peter Hillmen, Chris Fegan, Anna Schuh
exaly  

Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase

Circulation, 2020
Ling Xiao, Joe-Elie Salem, Sebastian Clauss   +2 more
exaly  

Ibrutinib in der Langzeitbetrachtung [PDF]

Info Onkologie, 2016
openaire   +1 more source